0 239

Cited 4 times in

Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.

Authors
 Dong Soo Kim  ;  Gwang Cheon Jang  ;  Sung-Ho Cha  ;  Soo-Han Choi  ;  Hwang Min Kim  ;  Ji Hong Kim  ;  Jin Han Kang  ;  Jong-Hyun Kim  ;  Ki Hwan Kim  ;  Joon Bang  ;  Zulaikha Naimi  ;  Alain Bouckenooghe  ;  Valérie Bosch-Castells  ;  Guy Houillon 
Citation
 PEDIATRIC INFECTIOUS DISEASE JOURNAL, Vol.35(2) : 60-64, 2016 
Journal Title
 PEDIATRIC INFECTIOUS DISEASE JOURNAL 
ISSN
 0891-3668 
Issue Date
2016
MeSH
Antibodies, Neutralizing/blood* ; Antibodies, Viral/blood ; Child, Preschool ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Encephalitis, Japanese/prevention & control* ; Female ; Humans ; Immunization, Secondary/adverse effects* ; Infant ; Japanese Encephalitis Vaccines/administration & dosage ; Japanese Encephalitis Vaccines/adverse effects* ; Japanese Encephalitis Vaccines/immunology* ; Male ; Republic of Korea ; Treatment Outcome ; Vaccines, Attenuated/administration & dosage ; Vaccines, Attenuated/adverse effects ; Vaccines, Attenuated/immunology ; Viral Plaque Assay
Keywords
Japanese encephalitis ; live-attenuated vaccine ; booster
Abstract
BACKGROUND: This study evaluated the effect of a booster vaccination of a new, live attenuated, Japanese encephalitis chimeric vaccine (JE-CV). Previously this vaccine has been used as a booster 12 months after priming with an inactivated vaccine and at >24 months after priming with the same JE-CV. This study evaluates the immunogenicity and safety of the JE-CV given at 12-24 months after JE-CV priming. METHODS: Phase III, open-label study in the Republic of Korea in which 119 children previously vaccinated with JE-CV at 12-24 months of age received a JE-CV booster at 12-24 months after primary vaccination. JE neutralizing antibody titers were measured using >50% plaque reduction neutralization test prebooster and 1 month postbooster vaccination. Seroprotection (SP) was defined as ≥10 (1/dil). Safety was assessed for 28 days postvaccination by parental reports. Serious adverse events were monitored for 6 months postvaccination. RESULTS: Antibody persistence was high prebooster (SP rate 93.5%). There was a strong anamnestic response postbooster vaccination, with an SP rate of 100% and a >50-fold increase in geometric mean titer from the prebooster level. Both antibody persistence and the booster response were independent of whether the booster was given at 12-17 or 18-24 months. The safety profile was good and comparable with the primary vaccination; there were no vaccine-related serious adverse events and no deaths. CONCLUSIONS: This study confirms the suitability of a JE-CV booster vaccination at 12-24 months after a primary dose of the same vaccine given at 12-24 months of age in children in the Republic of Korea.
Full Text
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00006454-201602000-00021&LSLINK=80&D=ovft
DOI
10.1097/INF.0000000000000967
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Ki Hwan(김기환)
Kim, Dong Soo(김동수)
Kim, Ji Hong(김지홍) ORCID logo https://orcid.org/0000-0001-5352-5423
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/146258
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse